Developer docs
API playgroundTry for free, no card

Search company profiles

ENTEROME

Full company profile

uuid0000n6x

Namestring
ENTEROME
Legal namestring
Enterome SA
Websiteurl
enterome.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Enterome is a clinical-stage biopharmaceutical company founded in 2012 in Paris, France, developing immunomodulatory therapeutics derived from the human gut microbiome. The company's core technology is the Mimicry drug discovery platform, which mines a proprietary database of more than 20 million full-length commensal bacterial proteins using proprietary biocomputational tools (including the GeneMark-HM gene prediction software co-developed with Gene Probe Inc.) to identify bacterial peptides that closely mimic human tumor-associated antigens, hormones, or cytokines. From this platform, Enterome has built three therapeutic franchises: OncoMimics for cancer (lead candidate EO2463 in indolent non-Hodgkin lymphoma with FDA Fast Track and Orphan Drug Designations; EO2401 in glioblastoma and adrenal tumors; EO4010 in metastatic colorectal cancer), EndoMimics for inflammatory and autoimmune diseases (lead candidate EB1010 partnered with Nestlé Health Science for food allergies and IBD), and AllerMimics, a new generation of MHC-II restricted allergen mimics for food allergies.

The company's business model is that of a venture-backed pre-commercial biopharma: it generates no product revenue today and funds operations through equity financing (~€155 million raised across 10+ rounds from 2011 to 2025, including a €46.3M round in June 2020 and a $19M round in June 2025), strategic grants (e.g., €3M from LLS TAP in October 2023), and partnership economics from co-development and licensing agreements (Nestlé Health Science for EndoMimics/EB1010; Takeda for sibofimloc). Future revenue is expected to come from pharmaceutical product sales, milestone payments, and royalties on net sales through partnerships for global commercialization. Enterome's customer base today consists of clinical trial investigator sites (Mayo Clinic, Fred Hutchinson, Dana-Farber, MD Anderson) and pharmaceutical/financial partners rather than commercial end-buyers. Leadership includes co-founder/CEO Pierre Belichard, Chairman Peter Hirth (co-founder of Plexxikon, sold to Daiichi Sankyo), CMO Jan Fagerberg (ex-Roche, ex-Amgen), and board members representing IFLI, Seventure Partners, Lundbeckfonden BioCapital, Primo Capital, and SymBiosis.

Short descriptiontext

Enterome is a clinical-stage Paris-based biopharmaceutical company developing microbiome-derived peptide immunotherapies (OncoMimics, EndoMimics, AllerMimics) for cancer, inflammatory diseases, and food allergies, with lead candidate EO2463 in Phase 1/2 trials for indolent non-Hodgkin lymphoma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer immunotherapy, microbiome therapeutics, peptide drug discovery, immuno-oncology treatments, clinical-stage biopharmaceutical
Industry4 codes
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKAAAD
Food Allergy Evaluation & Management
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Immuno-Oncology Therapeutics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Pre-revenue clinical stage company. Future revenue expected from commercialization of OncoMimics™ pipeline candidates (EO2463, EO2401, EO4010) upon regulatory approval. Company has received €3M strategic investment from LLS TAP and $19M private financing to fund clinical development.

enterome.com
2Partnership and Licensing Revenue
TypeLicensing Royalties
Description

Co-development and licensing agreements with pharmaceutical partners such as Nestlé Health Science (for EndoMimics™ EB1010) and Takeda (for sibofimloc). May include upfront payments, milestone payments, and royalties on net sales.

enterome.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1OncoMimics
Description

A specific combination of bacterial peptides derived from gut microbiome that closely mimic tumor-associated antigens (TAAs) or lineage-specific markers in solid and liquid tumors, generating powerful immune responses against cancer cells.

enterome.com
+2 more records
Core offering1 text field

Enterome is a clinical-stage biopharmaceutical company developing off-the-shelf, multi-targeted cancer immunotherapies derived from gut microbiome peptides. Its lead candidates include EO2463 for indolent non-Hodgkin lymphoma, EO2401 for glioblastoma and adrenal tumors, and EO4010 for metastatic colorectal cancer. The company also develops EndoMimics™ oral bioactives for inflammatory/autoimmune diseases (lead EB1010, partnered with Nestlé Health Science) and AllerMimics™ therapeutics for food allergies, all powered by its proprietary Mimicry drug discovery platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 90% immune response rate (43/48 patients) with EO2463 in indolent NHL
+6 more records
Product overview1 text field

ENTEROME is a clinical-stage biopharmaceutical company pioneering OncoMimics™, a new class of off-the-shelf, multi-targeted in vivo immune therapies. The company's core technology platform uses proprietary biocomputational tools and machine learning to mine a database of 20+ million gut microbiome proteins to identify bacterial peptides that closely mimic tumor-associated antigens. The OncoMimics™ approach activates pre-existing effector-memory CD8+ T cells to generate rapid, potent cytotoxic responses against cancer cells. ENTEROME's proprietary clinical programs include EO2463 (Phase 2 for indolent non-Hodgkin lymphoma), EO2401 (Phase 1/2 for glioblastoma and adrenal tumors), and EO4010 (Phase 1/2 for metastatic colorectal cancer). The company also maintains pipeline platforms in EndoMimics™ (for inflammatory diseases, including partnered EB1010 with Nestlé Health Science) and AllerMimics™ (for food allergies).

Product and service4 records
1EO2463
CategoryClinical Program - Oncology
Description

Off-the-shelf OncoMimics™ active immunotherapy combining four synthetic peptides (mimics of CD20, CD22, CD37, and CD268/BAFF-R B-cell lineage markers) plus CD4 helper peptide UCP2. Currently in Phase 2 SIDNEY trial for indolent non-Hodgkin lymphoma as monotherapy in watch-and-wait patients and in combination with rituximab/lenalidomide. Has received FDA Fast Track and Orphan Drug Designations for follicular lymphoma.

2EO2401
CategoryClinical Program - Oncology
Description

Off-the-shelf OncoMimics™ multi-targeted immunotherapy combining three peptides (EO2316, EO2317, EO2318) that mimic tumor-associated antigens IL13Ra2, BIRC5/survivin, and FOXM1, plus CD4 helper peptide UCP2. In Phase 1/2 ROSALIE trial for recurrent glioblastoma (completed enrollment of 100 patients) and SPENCER trial for adrenal tumors.

3EO4010
CategoryClinical Program - Oncology
Description

OncoMimics™ peptide-based immunotherapy combining five microbial-derived peptides targeting tumor-associated antigens BIRC5, FOXM1, UBE2C, CDC20, and KIF2C commonly observed in colorectal cancer patients. In Phase 1/2 AUDREY trial for metastatic colorectal cancer.

4EB1010
CategoryPartnered Clinical Program - Immunology
Description

Lead EndoMimics™ compound being co-developed with Nestlé Health Science; a potent local inducer of IL-10 designed for improved therapeutic outcomes in food allergies and inflammatory bowel disease (IBD).

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1BIOASTER Institute
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-02-03
Description

Research collaboration to provide new insights into immunological mechanisms underpinning Enterome's Oncomimicry platform. Leverages BIOASTER's expertise in microbiome sciences, microbiology engineering, immune-monitoring, and gnotobiology using proprietary GNOTOMICE model.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-development partnership to successfully develop and commercialize Enterome's lead EndoMimics pipeline candidate EB1010, a potent local inducer of IL-10 targeting food allergies and inflammatory bowel disease (IBD). EB1010 discovered using Enterome's Mimicry platform, expected to enter clinical trials in 2023. Partnership also aims to identify and create a pipeline of AllerMimics for food allergies with initial focus on peanut allergens.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Global licensing, co-development and co-commercialization partnership for sibofimloc (TAK-018), a first-in-class gut-restricted FimH-blocker for Crohn's disease. Sibofimloc is advancing through Phase 2a clinical trial with data readout expected H1 2023. Enterome's unique technologies validated the FimH target as underlying cause of Crohn's disease.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large mRNA-based immunotherapy company with multiple oncology vaccine programs including individualized neoantigen therapies and off-the-shelf FixVac candidates. Competes in cancer immunotherapy space with significantly greater resources and pipeline breadth.

2Hookipa Pharma
TypeEmerging player
Description

Clinical-stage immuno-oncology company developing arenavirus-based immunotherapies for cancer and infectious diseases. Comparable in clinical stage, oncology immunotherapy focus, and emerging biotech profile with platform-based approach.

TypeDirect peer
Description

Clinical-stage immuno-oncology company developing synthetic long peptide (SLP) vaccines targeting HPV-related cancers and other solid tumors. Direct competitor in therapeutic cancer peptide vaccines, with overlapping management connections (Enterome's CMO Jan Fagerberg was previously ISA's CMO).

TypeEmerging player
Description

Clinical-stage cell therapy company developing SPEAR T-cell therapies for solid tumors. Comparable in clinical-stage oncology immunotherapy development, though focused on cell therapy rather than peptide vaccines.

TypeBroad incumbent
Description

Major mRNA therapeutics company with oncology vaccine pipeline (mRNA-4157/V940) in melanoma and other solid tumors. Competes with Enterome in next-generation cancer immunotherapy and has significantly greater financial and clinical development resources.

TypeDirect peer
Description

Clinical-stage biotech developing off-the-shelf viral vector-based neoantigen cancer vaccines. Competes in the cancer immunotherapy vaccine space targeting solid tumors with similar strategic positioning to Enterome's OncoMimics platform.

TypeDirect peer
Description

Clinical-stage immuno-oncology company developing off-the-shelf therapeutic cancer vaccines based on immune-modulating technologies. Direct competitor in the cancer peptide vaccine space with similar therapeutic approach and target indications.

TypeEmerging player
Description

Clinical-stage microbiome-based therapeutics company developing gut microbiota therapies for cancer and inflammatory diseases. Competes in the microbiome-derived therapeutics space with direct investor overlap (Seventure Partners' Isabelle de Cremoux serves on both boards).

TypeEmerging player
Description

Clinical-stage vaccine company developing novel conjugate vaccines and peptide immunotherapies. Board member connection (Peter Hirth is on Vaxcyte's board) and similar biotech-stage development profile in vaccine/immunotherapy space.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing TCR-based immunotherapies and cancer vaccines (IMA203, IMA401) for solid tumors. Competes in next-generation cancer immunotherapy with multi-platform approach and Phase 1/2 assets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ENTEROME

Immuno-Oncology Therapeuticsenterome.com

Enterome is a clinical-stage Paris-based biopharmaceutical company developing microbiome-derived peptide immunotherapies (OncoMimics, EndoMimics, AllerMimics) for cancer, inflammatory diseases, and food allergies, with lead candidate EO2463 in Phase 1/2 trials for indolent non-Hodgkin lymphoma.

What ENTEROME does

Enterome is a clinical-stage biopharmaceutical company founded in 2012 in Paris, France, developing immunomodulatory therapeutics derived from the human gut microbiome. The company's core technology is the Mimicry drug discovery platform, which mines a proprietary database of more than 20 million full-length commensal bacterial proteins using proprietary biocomputational tools (including the GeneMark-HM gene prediction software co-developed with Gene Probe Inc.) to identify bacterial peptides that closely mimic human tumor-associated antigens, hormones, or cytokines. From this platform, Enterome has built three therapeutic franchises: OncoMimics for cancer (lead candidate EO2463 in indolent non-Hodgkin lymphoma with FDA Fast Track and Orphan Drug Designations; EO2401 in glioblastoma and adrenal tumors; EO4010 in metastatic colorectal cancer), EndoMimics for inflammatory and autoimmune diseases (lead candidate EB1010 partnered with Nestlé Health Science for food allergies and IBD), and AllerMimics, a new generation of MHC-II restricted allergen mimics for food allergies.

The company's business model is that of a venture-backed pre-commercial biopharma: it generates no product revenue today and funds operations through equity financing (~€155 million raised across 10+ rounds from 2011 to 2025, including a €46.3M round in June 2020 and a $19M round in June 2025), strategic grants (e.g., €3M from LLS TAP in October 2023), and partnership economics from co-development and licensing agreements (Nestlé Health Science for EndoMimics/EB1010; Takeda for sibofimloc). Future revenue is expected to come from pharmaceutical product sales, milestone payments, and royalties on net sales through partnerships for global commercialization. Enterome's customer base today consists of clinical trial investigator sites (Mayo Clinic, Fred Hutchinson, Dana-Farber, MD Anderson) and pharmaceutical/financial partners rather than commercial end-buyers. Leadership includes co-founder/CEO Pierre Belichard, Chairman Peter Hirth (co-founder of Plexxikon, sold to Daiichi Sankyo), CMO Jan Fagerberg (ex-Roche, ex-Amgen), and board members representing IFLI, Seventure Partners, Lundbeckfonden BioCapital, Primo Capital, and SymBiosis.

ENTEROME firmographics

Firmographics
Name
ENTEROME
Legal name
Enterome SA
Website
https://enterome.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
Enterome is a clinical-stage Paris-based biopharmaceutical company developing microbiome-derived peptide immunotherapies (OncoMimics, EndoMimics, AllerMimics) for cancer, inflammatory diseases, and food allergies, with lead candidate EO2463 in Phase 1/2 trials for indolent non-Hodgkin lymphoma.
Ownership category
akta.pro rank

ENTEROME industry classification

Industry
Product category
Immuno-Oncology Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKAAAD
Food Allergy Evaluation & Management
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Cancer immunotherapy
  • Microbiome therapeutics
  • Peptide drug discovery
  • Immuno-oncology treatments
  • Clinical-stage biopharmaceutical

Where ENTEROME is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices1 record

Markets served

ENTEROME business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Revenue: Pre-revenue clinical stage company. Future revenue expected from commercialization of OncoMimics™ pipeline candidates (EO2463, EO2401, EO4010) upon regulatory approval. Company has received €3M strategic investment from LLS TAP and $19M private financing to fund clinical development.
  2. Partnership and Licensing Revenue: Co-development and licensing agreements with pharmaceutical partners such as Nestlé Health Science (for EndoMimics™ EB1010) and Takeda (for sibofimloc). May include upfront payments, milestone payments, and royalties on net sales.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

ENTEROME product offering

Product offering

Core offering

Enterome is a clinical-stage biopharmaceutical company developing off-the-shelf, multi-targeted cancer immunotherapies derived from gut microbiome peptides. Its lead candidates include EO2463 for indolent non-Hodgkin lymphoma, EO2401 for glioblastoma and adrenal tumors, and EO4010 for metastatic colorectal cancer. The company also develops EndoMimics™ oral bioactives for inflammatory/autoimmune diseases (lead EB1010, partnered with Nestlé Health Science) and AllerMimics™ therapeutics for food allergies, all powered by its proprietary Mimicry drug discovery platform.

Product overview

ENTEROME is a clinical-stage biopharmaceutical company pioneering OncoMimics™, a new class of off-the-shelf, multi-targeted in vivo immune therapies. The company's core technology platform uses proprietary biocomputational tools and machine learning to mine a database of 20+ million gut microbiome proteins to identify bacterial peptides that closely mimic tumor-associated antigens. The OncoMimics™ approach activates pre-existing effector-memory CD8+ T cells to generate rapid, potent cytotoxic responses against cancer cells. ENTEROME's proprietary clinical programs include EO2463 (Phase 2 for indolent non-Hodgkin lymphoma), EO2401 (Phase 1/2 for glioblastoma and adrenal tumors), and EO4010 (Phase 1/2 for metastatic colorectal cancer). The company also maintains pipeline platforms in EndoMimics™ (for inflammatory diseases, including partnered EB1010 with Nestlé Health Science) and AllerMimics™ (for food allergies).

Differentiator

Problem solved

Functional benefit

Brands

  • OncoMimics: A specific combination of bacterial peptides derived from gut microbiome that closely mimic tumor-associated antigens (TAAs) or lineage-specific markers in solid and liquid tumors, generating powerful immune responses against cancer cells.
  • EndoMimics
  • AllerMimics

Products and services

  • EO2463 Off-the-shelf OncoMimics™ active immunotherapy combining four synthetic peptides (mimics of CD20, CD22, CD37, and CD268/BAFF-R B-cell lineage markers) plus CD4 helper peptide UCP2. Currently in Phase 2 SIDNEY trial for indolent non-Hodgkin lymphoma as monotherapy in watch-and-wait patients and in combination with rituximab/lenalidomide. Has received FDA Fast Track and Orphan Drug Designations for follicular lymphoma.
  • EO2401 Off-the-shelf OncoMimics™ multi-targeted immunotherapy combining three peptides (EO2316, EO2317, EO2318) that mimic tumor-associated antigens IL13Ra2, BIRC5/survivin, and FOXM1, plus CD4 helper peptide UCP2. In Phase 1/2 ROSALIE trial for recurrent glioblastoma (completed enrollment of 100 patients) and SPENCER trial for adrenal tumors.
  • EO4010 OncoMimics™ peptide-based immunotherapy combining five microbial-derived peptides targeting tumor-associated antigens BIRC5, FOXM1, UBE2C, CDC20, and KIF2C commonly observed in colorectal cancer patients. In Phase 1/2 AUDREY trial for metastatic colorectal cancer.
  • EB1010 Lead EndoMimics™ compound being co-developed with Nestlé Health Science; a potent local inducer of IL-10 designed for improved therapeutic outcomes in food allergies and inflammatory bowel disease (IBD).

Quantifiable outcome

  • 90% immune response rate (43/48 patients) with EO2463 in indolent NHL
  • +6 more outcomes

Companies that use ENTEROME

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles2 records

ENTEROME technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

ENTEROME partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor and core.

  • BIOASTER InstituteminorStrategic or Co-development Partner · 3 February 2020Research collaboration to provide new insights into immunological mechanisms underpinning Enterome's Oncomimicry platform. Leverages BIOASTER's expertise in microbiome sciences, microbiology engineering, immune-monitoring, and gnotobiology using proprietary GNOTOMICE model.
  • Nestlé Health SciencecoreStrategic or Co-development PartnerCo-development partnership to successfully develop and commercialize Enterome's lead EndoMimics pipeline candidate EB1010, a potent local inducer of IL-10 targeting food allergies and inflammatory bowel disease (IBD). EB1010 discovered using Enterome's Mimicry platform, expected to enter clinical trials in 2023. Partnership also aims to identify and create a pipeline of AllerMimics for food allergies with initial focus on peanut allergens.
  • Takeda Pharmaceutical CompanycoreStrategic or Co-development PartnerGlobal licensing, co-development and co-commercialization partnership for sibofimloc (TAK-018), a first-in-class gut-restricted FimH-blocker for Crohn's disease. Sibofimloc is advancing through Phase 2a clinical trial with data readout expected H1 2023. Enterome's unique technologies validated the FimH target as underlying cause of Crohn's disease.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

ENTEROME competitors and assessment

Company assessment

Broad incumbents

  • BioNTech: Large mRNA-based immunotherapy company with multiple oncology vaccine programs including individualized neoantigen therapies and off-the-shelf FixVac candidates. Competes in cancer immunotherapy space with significantly greater resources and pipeline breadth.
  • Moderna: Major mRNA therapeutics company with oncology vaccine pipeline (mRNA-4157/V940) in melanoma and other solid tumors. Competes with Enterome in next-generation cancer immunotherapy and has significantly greater financial and clinical development resources.

Emerging players

  • Hookipa Pharma: Clinical-stage immuno-oncology company developing arenavirus-based immunotherapies for cancer and infectious diseases. Comparable in clinical stage, oncology immunotherapy focus, and emerging biotech profile with platform-based approach.
  • Adaptimmune Therapeutics: Clinical-stage cell therapy company developing SPEAR T-cell therapies for solid tumors. Comparable in clinical-stage oncology immunotherapy development, though focused on cell therapy rather than peptide vaccines.
  • MaaT Pharma: Clinical-stage microbiome-based therapeutics company developing gut microbiota therapies for cancer and inflammatory diseases. Competes in the microbiome-derived therapeutics space with direct investor overlap (Seventure Partners' Isabelle de Cremoux serves on both boards).
  • Vaxcyte: Clinical-stage vaccine company developing novel conjugate vaccines and peptide immunotherapies. Board member connection (Peter Hirth is on Vaxcyte's board) and similar biotech-stage development profile in vaccine/immunotherapy space.

Direct peers

  • ISA Pharmaceuticals: Clinical-stage immuno-oncology company developing synthetic long peptide (SLP) vaccines targeting HPV-related cancers and other solid tumors. Direct competitor in therapeutic cancer peptide vaccines, with overlapping management connections (Enterome's CMO Jan Fagerberg was previously ISA's CMO).
  • Nouscom: Clinical-stage biotech developing off-the-shelf viral vector-based neoantigen cancer vaccines. Competes in the cancer immunotherapy vaccine space targeting solid tumors with similar strategic positioning to Enterome's OncoMimics platform.
  • IO Biotech: Clinical-stage immuno-oncology company developing off-the-shelf therapeutic cancer vaccines based on immune-modulating technologies. Direct competitor in the cancer peptide vaccine space with similar therapeutic approach and target indications.
  • Immatics: Clinical-stage biopharmaceutical company developing TCR-based immunotherapies and cancer vaccines (IMA203, IMA401) for solid tumors. Competes in next-generation cancer immunotherapy with multi-platform approach and Phase 1/2 assets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

ENTEROME social profiles

Digital presence

ENTEROME financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ENTEROME leadership team

Management profile

Number of profiles

Profiles13 records

ENTEROME funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ENTEROME M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ENTEROME

What does ENTEROME do?

Enterome is a clinical-stage biopharmaceutical company developing off-the-shelf, multi-targeted cancer immunotherapies derived from gut microbiome peptides. Its lead candidates include EO2463 for indolent non-Hodgkin lymphoma, EO2401 for glioblastoma and adrenal tumors, and EO4010 for metastatic colorectal cancer. The company also develops EndoMimics™ oral bioactives for inflammatory/autoimmune diseases (lead EB1010, partnered with Nestlé Health Science) and AllerMimics™ therapeutics for food allergies, all powered by its proprietary Mimicry drug discovery platform.

Is ENTEROME a public or private company?

ENTEROME is a private company. It is classified as venture growth investor backed and is currently operating.

When was ENTEROME founded?

ENTEROME was founded in 2012. It employs 11 to 50 people.

Where is ENTEROME based?

ENTEROME is headquartered in Paris, France, in the Europe region.

How does ENTEROME make money?

Two revenue lines are on record. Pharmaceutical Product Revenue is the primary driver. The others are partnership and Licensing Revenue.

Who are ENTEROME's main competitors?

Broad incumbents on record are BioNTech and Moderna. Emerging players are Hookipa Pharma, Adaptimmune Therapeutics, MaaT Pharma and Vaxcyte. Direct peers are ISA Pharmaceuticals, Nouscom, IO Biotech and Immatics.

Does ENTEROME have an API?

No public API is recorded for ENTEROME.

What industry is ENTEROME in?

ENTEROME's product category is Immuno-Oncology Therapeutics. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAKAAAD, Food Allergy Evaluation & Management. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrtimesUS Human Microbiome Market Growth: Advancing Next-Generation Healthcare Solutions – PR TimesThe Insight Partners report projects the US human microbiome-based drugs and diagnostics market to grow at a 15.1% CAGR from 2026 to 2034, driven by chronic disease burden, precision medicine adoption and technological advances. It cites fecal microbiota transplantation, microbiome-based diagnostics and cancer immunotherapy as emerging trends, and names Second Genome, Enterome Bioscience, Yakult, Merck and others as key players.FinancialContent Business PageEnterome Phase 2 data show EO2463-induced CD8 T-cell expansion correlates with progression-free survival in patients with indolent non-Hodgkin lymphoma in the watch-and-wait settingEnterome SA announced positive interim Phase 1/2 data showing EO2463-induced CD8 T-cell expansion statistically significantly correlates with longer progression-free survival (HR=0.18, p=0.020) in patients with indolent non-Hodgkin lymphoma managed in a watch-and-wait setting. The Phase 1/2 SIDNEY trial also demonstrated that higher CD8 T-cell expansion was significantly associated with complete response rates in the relapsed/refractory cohort treated with EO2463 plus lenalidomide and rituximab. Enterome indicated it is advancing EO2463 toward registrational clinical development and is in active discussions with potential investors and partners, having received FDA Orphan Drug Designation for follicular lymphoma in May 2026.GlobeNewswireEnterome Phase 2 data show EO2463-induced CD8 T-cell expansion correlates with progression-free survival in patients with indolent non-Hodgkin lymphoma in the watch-and-wait settingEnterome SA announced positive interim Phase 1/2 SIDNEY trial data showing that EO2463-induced CD8 T-cell expansion statistically significantly correlates with longer progression-free survival as monotherapy in indolent Non-Hodgkin Lymphoma patients managed in a watch-and-wait setting (HR=0.18, log-rank p=0.020), and with complete response rates when combined with lenalidomide and rituximab (p=0.0073). The company believes these findings support EO2463-induced CD8 T-cell expansion as a potential predictive biomarker and that EO2463 is ready to enter registrational clinical development as a first-in-class therapeutic for iNHL.BioSpaceEnterome Phase 2 data show EO2463-induced CD8 T-cell expansion correlates with progression-free survival in patients with indolent non-Hodgkin lymphoma in the watch-and-wait settingEnterome presented Phase 2 data from the SIDNEY trial showing EO2463-induced CD8 T-cell expansion correlates with longer progression-free survival in indolent non-Hodgkin lymphoma patients on watch-and-wait monotherapy. The same expansion also correlates with complete response in relapsed/refractory patients treated with EO2463 plus lenalidomide and rituximab. The company plans to present EO4010 data at ESMO 2026.GlobeNewswireEnterome presents Phase 1/2 iNHL interim data at EHA demonstrating durable OncoMimics™-induced CD8 T cell responses and clinical activityEnterome SA presented positive interim Phase 1/2 data for its OncoMimics™ EO2463 immunotherapy in patients with indolent non-Hodgkin lymphoma at the EHA 2026 Congress, with 90% immune response rate (43/48 patients) and 74% objective response rate with 61% complete response in combination therapy. The data demonstrated durable CD8 T-cell expansion up to 34 months with significant association between T-cell expansion and clinical response. The FDA granted Orphan Drug Designation for EO2463 in follicular lymphoma in May 2026, and the company is actively seeking partners and investors to advance registrational development.BioSpaceEnterome presents Phase 1/2 iNHL interim data at EHA demonstrating durable OncoMimics™-induced CD8 T cell responses and clinical activityEnterome presented interim data from the SIDNEY Phase 1/2 study of EO2463 in indolent non-Hodgkin lymphoma at EHA 2026. The data showed well-tolerated treatment, 90% positive immune responses, and durable CD8 T cell expansion, with monotherapy ORR of 41% and combination with R2 ORR of 74%. The company plans to seek partners for registrational development.Targeted OncologyFDA Orphan Drug Status Awarded to EO2463 in Indolent Non-Hodgkin LymphomaThe FDA granted orphan drug designation (ODD) to EO2463, a cancer peptide therapeutic vaccine developed by Enterome, for treating patients with indolent non-Hodgkin lymphoma in the watch-and-wait setting. The designation provides 7 years of market exclusivity in the United States upon potential approval and builds on a previous FDA fast track designation granted in October 2025. The milestone is supported by data from the ongoing SIDNEY phase 1/2 trial, with additional phase 2 results to be presented at the 2026 European Hematology Association Congress.GlobeNewswireEnterome receives U.S. FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat “watch-and-wait” indolent non-Hodgkin lymphomaThe U.S. FDA granted Orphan Drug Designation to Enterome's EO2463 for treating indolent non-Hodgkin lymphoma in the "watch-and-wait" setting. Clinical data from the SIDNEY trial showed a 52.6% objective response rate as monotherapy in watch-and-wait follicular lymphoma patients and a 60% complete response rate when combined with lenalidomide and rituximab in relapsed/refractory patients. The company is actively engaging with potential partners and investors to advance EO2463 toward registrational development.BioSpaceEnterome receives U.S. FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat “watch-and-wait” indolent non-Hodgkin lymphomaEnterome announced the U.S. FDA granted Orphan Drug Designation to EO2463 for indolent non-Hodgkin lymphoma in the watch-and-wait setting. Clinical data showed a 52.6% objective response rate in 19 evaluable patients, and the company is engaging with partners to advance development.BioSpaceEnterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomesEnterome presented interim data from the SIDNEY Phase 2 trial of EO2463 at EHA, showing rapid expansion of B cell target-specific CD8 T-cells that correlated with clinical responses. The company plans to advance EO2463 into a Phase 3 registrational trial.